{"id":71436,"date":"2026-05-20T11:25:00","date_gmt":"2026-05-20T11:25:00","guid":{"rendered":"https:\/\/medsbase.com\/hcg-peptide\/"},"modified":"2026-10-15T10:33:56","modified_gmt":"2026-10-15T10:33:56","slug":"hcg-peptide","status":"publish","type":"product","link":"https:\/\/medsbase.com\/pt-pt\/product\/hcg-peptide\/","title":{"rendered":"HCG (Human Chorionic Gonadotropin) \u2014 Pharmaceutical Grade"},"content":{"rendered":"<p><!-- medsbase-tldr-answer --><\/p>\n<div style=\"background: #fff8e1; border-left: 4px solid #f5a623; padding: 18px 22px; margin: 18px 0; border-radius: 4px;\">\n<h3 style=\"margin: 0 0 8px 0; font-size: 16px; color: #1a4a6b;\">Quick Answer \u2014 What is HCG (pharmaceutical-grade)?<\/h3>\n<p style=\"margin: 0;\"><strong>HCG<\/strong> (Gonadotrofina Cori\u00f3nica Humana) \u00e9 uma hormona glicoproteica composta por duas subunidades n\u00e3o covalentemente associadas (\u03b1, 92 amino\u00e1cidos \u2014 partilhada com LH\/FSH\/TSH; \u03b2, 145 amino\u00e1cidos \u2014 \u00fanica para HCG), com um peso molecular combinado aproximado de ~36,7 kDa. \u00c9 a ferramenta farmacol\u00f3gica can\u00f3nica para ativar o <strong>recetor LH\/CG (LHCGR)<\/strong> on Leydig cells (driving testosterone production in male study models) and ovarian theca \/ granulosa cells (driving follicular maturation and ovulation in female reproductive studies). The pharmaceutical-grade material supplied here is the urinary-extracted glycoform (CAS 9002-61-3) at \u226599% HPLC purity, lyophilized in 5,000 IU or 10,000 IU vials. It is <em>funcionalmente distinto<\/em> from the recombinant rHCG (choriogonadotropin alfa, CAS 56832-30-5) used in some clinical preparations. Supplied ready for use.<\/p>\n<\/div>\n<div class=\"medsbase-trust-strip\" style=\"background: #f4f8fb; border: 1px solid #d8e3eb; padding: 12px 16px; margin: 16px 0; border-radius: 4px; font-size: 14px;\"><strong>O que obt\u00e9m com a MedsBase:<\/strong> Pharmaceutical-grade lyophilized peptides &middot; HPLC &ge;99% purity (COA on request) &middot; Discreet protective packaging &middot; Worldwide peptide courier &middot; 1,400+ verified <a href=\"https:\/\/medsbase.com\/pt-pt\/reviews\/\">de clientes<\/a><\/div>\n<p class=\"medsbase-reship-line\" style=\"font-size: 14px; color: #444; margin: 8px 0 18px;\">\ud83d\udce6 Cada encomenda est\u00e1 coberta pela nossa <a href=\"https:\/\/medsbase.com\/pt-pt\/medsbase-re-shipment-assurance-policy\/\"><strong>Pol\u00edtica de Garantia de Reenvio<\/strong><\/a> \u2014 se a sua encomenda n\u00e3o chegar no prazo de 20 dias \u00fateis, reenviamo-la.<\/p>\n<table class=\"medsbase-spec-table\" style=\"width: 100%; border-collapse: collapse; margin: 18px 0; font-size: 14px;\">\n<thead>\n<tr style=\"background: #2c7cb0; color: #fff;\">\n<th style=\"padding: 8px 12px; text-align: left; width: 30%;\">Especifica\u00e7\u00e3o<\/th>\n<th style=\"padding: 8px 12px; text-align: left;\">Detalhe<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Classe do Composto<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">Hormona glicoproteica heterodim\u00e9rica (subunidades \u03b1 + \u03b2); agonista do recetor LH\/CG (LHCGR); hormona pept\u00eddica<\/td>\n<\/tr>\n<tr style=\"background: #fff;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Nome Qu\u00edmico<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">Gonadotrofina Cori\u00f3nica Humana (glicoforma extra\u00edda da urina; uHCG)<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>N\u00famero CAS<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">9002-61-3 (HCG urin\u00e1ria); 56832-30-5 (coriogonadotropina alfa recombinante \u2014 n\u00e3o a forma fornecida aqui)<\/td>\n<\/tr>\n<tr style=\"background: #fff;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Estrutura das Subunidades<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">Heterod\u00edmero de duas subunidades associadas n\u00e3o covalentemente: subunidade \u03b1 (92 amino\u00e1cidos, partilhada com LH\/FSH\/TSH) e subunidade \u03b2 (145 amino\u00e1cidos, exclusiva da HCG). Ambas as subunidades s\u00e3o extensamente N- e O-glicosiladas \u2014 o elevado conte\u00fado de \u00e1cido si\u00e1lico da subunidade \u03b2 \u00e9 respons\u00e1vel pela meia-vida plasm\u00e1tica excecionalmente longa da HCG em rela\u00e7\u00e3o \u00e0 LH.<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Peso Molecular<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">~36.700 Da (~36,7 kDa) heterod\u00edmero combinado; subunidade \u03b1 ~14 kDa, subunidade \u03b2 ~22 kDa (fortemente glicosilada)<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>F\u00f3rmula Molecular<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">Glicoprote\u00edna heterodim\u00e9rica \u2014 subunidade \u03b1 (92 aa, partilhada com LH\/FSH\/TSH) + subunidade \u03b2 (145 aa, espec\u00edfica da hCG). A elevada sialila\u00e7\u00e3o (~30% p\/p de hidratos de carbono) confere uma meia-vida plasm\u00e1tica de 33\u201337 h. N\u00e3o existe uma \u00fanica f\u00f3rmula molecular devido \u00e0 composi\u00e7\u00e3o vari\u00e1vel das glicoformas; peso molecular apenas proteico ~25 kDa, peso molecular totalmente glicosilado ~36,7 kDa.<\/td>\n<\/tr>\n<tr style=\"background: #fff;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Mechanism<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">Liga e ativa o recetor de LH\/CG (<strong>LHCGR<\/strong>) \u2014 um GPCR acoplado a Gs expresso nas c\u00e9lulas de Leydig (test\u00edculo) e nas c\u00e9lulas da teca\/granulosa do ov\u00e1rio. A ativa\u00e7\u00e3o do recetor estimula a adenilato ciclase, aumenta o cAMP intracelular, ativa a PKA e induz as enzimas esteroidog\u00e9nicas (StAR, CYP17A1, CYP11A1) que impulsionam a bioss\u00edntese de novo de testosterona (masculino) ou a bioss\u00edntese de estrog\u00e9nio\/progesterona (feminino). A HCG e a LH partilham o mesmo recetor e a mesma cascata de sinaliza\u00e7\u00e3o.<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Convers\u00e3o de UI para mg<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">~9.300 UI por mg de material altamente purificado (refer\u00eancia do 5.\u00ba Padr\u00e3o Internacional da OMS). 1 UI corresponde, portanto, a aproximadamente 108 ng de p\u00e9ptido puro. Um frasco de 5.000 UI cont\u00e9m ~0,54 mg de p\u00e9ptido; um frasco de 10.000 UI cont\u00e9m ~1,08 mg.<\/td>\n<\/tr>\n<tr style=\"background: #fff;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Meia-vida plasm\u00e1tica<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">Elimina\u00e7\u00e3o bif\u00e1sica \u2014 fase inicial ~6 h, fase terminal 33\u201337 h. Substancialmente mais longa do que a LH (~20 min) \u2014 devido ao elevado conte\u00fado de \u00e1cido si\u00e1lico dos glicanos da subunidade \u03b2, que reduz a depura\u00e7\u00e3o hep\u00e1tica.<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Forma<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">Lyophilized white-to-off-white amorphous powder; single-use vials. Supplied with a separate stopper-sealed lyophilized cake (no in-vial diluent).<\/td>\n<\/tr>\n<tr style=\"background: #fff;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Pureza<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">\u226599% (verificado por HPLC); ensaio biol\u00f3gico da OMS confirma pot\u00eancia de liga\u00e7\u00e3o ao LHCGR consistente com o 5.\u00ba Padr\u00e3o Internacional. COA dispon\u00edvel mediante pedido.<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Solubilidade<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">Reconstitute in bacteriostatic water (the standard supply diluent) at 1.0 mL per 5,000 IU (\u2192 5,000 IU\/mL working stock) or 2.0 mL per 10,000 IU (\u2192 5,000 IU\/mL); other dilutions per protocol. Mannitol-based lyophilization cake dissolves rapidly with gentle swirling \u2014 do not shake. Avoid vortexing (high-shear can dissociate the \u03b1\/\u03b2 heterodimer).<\/td>\n<\/tr>\n<tr style=\"background: #fff;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Armazenamento<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">Liofilizado: 2\u20138 \u00b0C fechado para stock de trabalho a curto prazo; \u221220 \u00b0C para armazenamento a longo prazo (est\u00e1vel \u226536 meses a \u221220 \u00b0C; \u226518 meses a 2\u20138 \u00b0C). Reconstitu\u00eddo: 2\u20138 \u00b0C, utilizar dentro de ~30 dias. Proteger da luz. <strong>N\u00e3o congelar material reconstitu\u00eddo<\/strong> \u2014 os ciclos de congela\u00e7\u00e3o-descongela\u00e7\u00e3o dissociam o heterod\u00edmero \u03b1\/\u03b2 e destroem a bioatividade.<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p><!-- \/medsbase-tldr-answer --><\/p>\n<h2>O que \u00e9 HCG?<\/h2>\n<p><strong>HCG<\/strong> (Human Chorionic Gonadotropin, CAS 9002-61-3) is a glycoprotein peptide hormone in the same gonadotropin family as luteinising hormone (LH), follicle-stimulating hormone (FSH), and thyroid-stimulating hormone (TSH). Like the other three, it is a heterodimer of an \u03b1-subunit (92 amino acids, identical across all four hormones) and a \u03b2-subunit (145 amino acids, unique to HCG). The \u03b1 and \u03b2 subunits are non-covalently associated and both are extensively glycosylated \u2014 the \u03b2-subunit alone carries four N-linked and four O-linked glycans, and the high sialic-acid content of these glycans is responsible for HCG&#8217;s exceptionally long plasma half-life relative to LH (33\u201337 h terminal, versus ~20 min for LH). Endogenous HCG is produced by the syncytiotrophoblast of the developing placenta during pregnancy, where it maintains the corpus luteum and progesterone production for the first ~10 weeks of gestation. Outside pregnancy it is not normally present at detectable levels; its appearance in serum or urine is therefore the basis of pregnancy testing. The pharmacological utility of HCG in studies, however, has nothing to do with this physiological role and everything to do with the fact that HCG binds and activates the same LH\/CG receptor (LHCGR) as endogenous LH \u2014 but with far longer duration of action. HCG is therefore the standard pharmacological tool for sustained LHCGR activation in studies that probes Leydig-cell function, gonadal steroidogenesis, spermatogenesis, follicular development, ovulation, and the HPG axis broadly. Two molecular forms of HCG exist in commerce: the urinary-extracted form (<strong>uHCG<\/strong>, CAS 9002-61-3), purificada da urina de mulheres gr\u00e1vidas, que \u00e9 a que fornecemos; e a forma recombinante (<strong>rHCG<\/strong> ou coriogonadotrofina alfa, CAS 56832-30-5), produzida em c\u00e9lulas CHO e utilizada em algumas prepara\u00e7\u00f5es cl\u00ednicas (Ovidrel \/ Ovitrelle). As duas formas t\u00eam a mesma sequ\u00eancia de amino\u00e1cidos e o mesmo perfil de liga\u00e7\u00e3o ao LHCGR, mas os padr\u00f5es de glicosila\u00e7\u00e3o diferem ligeiramente entre a extra\u00e7\u00e3o urin\u00e1ria e a express\u00e3o em c\u00e9lulas CHO \u2014 compara\u00e7\u00f5es publicadas em bioensaios relatam uma pot\u00eancia in vivo amplamente equivalente. <\/p>\n<h2>Mecanismo de A\u00e7\u00e3o \u2014 Ativa\u00e7\u00e3o do Recetor LH\/CG e Esteroidog\u00e9nese<\/h2>\n<p>O mecanismo da HCG est\u00e1 entre os mais caracterizados na farmacologia end\u00f3crina:<\/p>\n<ul>\n<li><strong>Liga\u00e7\u00e3o ao recetor LH\/CG (LHCGR)<\/strong> \u2014 O HCG liga-se ao LHCGR (um GPCR acoplado a Gs da classe A com um grande dom\u00ednio extracelular rico em repeti\u00e7\u00f5es de leucina), com alta afinidade e no mesmo local de liga\u00e7\u00e3o que o LH end\u00f3geno. A distribui\u00e7\u00e3o do recetor est\u00e1 restrita ao tecido gonadal: c\u00e9lulas de Leydig do test\u00edculo (homens), e c\u00e9lulas da teca ovariana, c\u00e9lulas da granulosa mural e c\u00e9lulas da granulosa luteinizadas (mulheres). O LHCGR tamb\u00e9m \u00e9 expresso em n\u00edveis mais baixos nas c\u00e9lulas do corpo l\u00fateo, onde o HCG sustenta a produ\u00e7\u00e3o de progesterona durante o in\u00edcio da gravidez.<\/li>\n<li><strong>Cascata de sinaliza\u00e7\u00e3o Gs-cAMP-PKA<\/strong> \u2014 O LHCGR ativado acopla-se ao G\u03b1s, aumentando o AMP c\u00edclico intracelular, ativando a PKA e induzindo a fosforila\u00e7\u00e3o do CREB e de outros fatores de transcri\u00e7\u00e3o a jusante. O cAMP tamb\u00e9m envolve o EPAC para alguns efeitos a jusante. A ativa\u00e7\u00e3o da PKA em c\u00e9lulas esteroidog\u00e9nicas aumenta especificamente a prote\u00edna StAR (prote\u00edna reguladora aguda esteroidog\u00e9nica), que transporta o colesterol atrav\u00e9s da membrana externa mitocondrial \u2014 o passo limitante da esteroidog\u00e9nese de novo.<\/li>\n<li><strong>Indu\u00e7\u00e3o de enzimas esteroidog\u00e9nicas<\/strong> \u2014 A ativa\u00e7\u00e3o sustentada do LHCGR pelo HCG induz a regula\u00e7\u00e3o transcricional da cascata de enzimas esteroidog\u00e9nicas: CYP11A1 (clivagem da cadeia lateral do colesterol), CYP17A1 (17\u03b1-hidroxilase \/ 17,20-liase), 3\u03b2-HSD e 17\u03b2-HSD. O resultado l\u00edquido nas c\u00e9lulas de Leydig \u00e9 a bioss\u00edntese sustentada de testosterona de novo; nas c\u00e9lulas da teca ovariana, a mesma cascata produz androstenediona (que as c\u00e9lulas da granulosa convertem em estradiol via CYP19A1 \/ aromatase sob estimula\u00e7\u00e3o do FSH).<\/li>\n<li><strong>Dura\u00e7\u00e3o funcional e taquifilaxia<\/strong> \u2014 A single HCG bolus produces sustained LHCGR activation lasting 5\u20137 days in study models, because of HCG&#8217;s long plasma half-life (33\u201337 h) and the LHCGR&#8217;s slow internalization kinetics. Repeated high-dose HCG dosing can produce LHCGR desensitization (tachyphylaxis) \u2014 a well-documented phenomenon in published Leydig-cell studies that is relevant to chronic-dosing protocols.<\/li>\n<li><strong>Feedback hipot\u00e1lamo-hipofis\u00e1rio<\/strong> \u2014 Like endogenous testosterone, HCG-driven testosterone output feeds back to the hypothalamus and pituitary to suppress GnRH and LH\/FSH secretion. In the context of suppressed-HPG studies (testosterone replacement, AAS exposure, or pharmacological HPG suppression), HCG bypasses the hypothalamic-pituitary blockade by acting directly at the Leydig-cell LHCGR \u2014 which is why HCG is the canonical tool for probing Leydig-cell preserved function under HPG suppression.<\/li>\n<\/ul>\n<p>HCG and LH activate the same receptor through the same cascade, but with two key practical differences: HCG produces longer, more sustained signalling per dose (because of its longer half-life), and HCG is administered exogenously while endogenous LH is pulsatile and centrally regulated. Study protocols that need sustained, controllable LHCGR activation use HCG; protocols that need pulsatile, physiological LHCGR activation use recombinant LH or GnRH-driven endogenous LH. <\/p>\n<h2>Published Evidence<\/h2>\n<p>HCG is used in clinical contexts that investigate:<\/p>\n<ul>\n<li><strong>Farmacologia do LHCGR \u2014 o agonista de refer\u00eancia can\u00f3nico<\/strong> \u2014 de longe, o ativador do recetor LH\/CG mais citado na literatura publicada; composto padr\u00e3o para estudos de cin\u00e9tica de internaliza\u00e7\u00e3o do recetor, estudos de vi\u00e9s de sinaliza\u00e7\u00e3o e desenvolvimento de novos moduladores de pequenas mol\u00e9culas direcionados ao LHCGR<\/li>\n<li><strong>Biologia das c\u00e9lulas de Leydig e esteroidog\u00e9nese gonadal<\/strong> \u2014 HCG is the standard pharmacological stimulus for de-novo testosterone biosynthesis in primary Leydig-cell culture and ex-vivo testicular slice preparations; widely used in studies on Leydig-cell function, mitochondrial cholesterol transport, StAR regulation, and steroidogenic-enzyme cascade kinetics<\/li>\n<li><strong>HPG-axis suppression-recovery<\/strong> \u2014 in study models where endogenous LH\/FSH has been suppressed (by exogenous testosterone administration, anabolic-androgenic-steroid exposure, or pharmacological GnRH antagonism), HCG acts directly at the Leydig-cell LHCGR to maintain testosterone output and preserve Leydig-cell function; the canonical tool for dissecting the HPG-axis suppression-recovery dynamics<\/li>\n<li><strong>Spermatogenesis studies<\/strong> \u2014 used in combination with FSH or FSH-analogues in published Sertoli-cell \/ spermatogonial-stem-cell studies; sustains the high-intratesticular-testosterone microenvironment required for spermatogenesis even in the face of suppressed circulating LH<\/li>\n<li><strong>Ovarian follicular development and ovulation studies<\/strong> \u2014 in female reproductive studies, HCG is used to mimic the LH surge that triggers final follicular maturation, oocyte meiotic resumption, and follicular rupture; standard tool in published ovulation-trigger protocols, oocyte-maturation studies, and luteinization studies<\/li>\n<li><strong>Biologia do corpo l\u00fateo<\/strong> \u2014 HCG sustains corpus-luteum function and progesterone production by direct LHCGR activation on luteal cells; used in published studies on the luteal phase and the luteo-placental transition<\/li>\n<li><strong>Farmacologia de recetores e agonismo enviesado<\/strong> \u2014 o LHCGR exibe sinaliza\u00e7\u00e3o enviesada cAMP vs arrestina, e a HCG \u00e9 o agonista total de refer\u00eancia contra o qual os ligantes enviesados (moduladores alost\u00e9ricos de pequenas mol\u00e9culas do LHCGR, ORG-43553, e outros) s\u00e3o comparados<\/li>\n<li><strong>Farmacologia comparativa vs LH e coriogonadotropina alfa recombinante<\/strong> \u2014 published studies has compared urinary-extracted HCG (uHCG, what we supply), recombinant HCG (rHCG \/ choriogonadotropin alfa), and recombinant LH (Luveris) head-to-head for receptor-binding, cAMP signalling, and in-vivo testosterone-output endpoints<\/li>\n<\/ul>\n<p>For broader context on HPG-axis and reproductive-system peptides in this catalogue, see <a href=\"https:\/\/medsbase.com\/pt-pt\/kisspeptin-10\/\">Kisspeptina-10<\/a> (o regulador hipotal\u00e2mico a montante do GnRH \u2014 o pept\u00eddeo do eixo HPG mais direto complementar \u00e0 HCG), <a href=\"https:\/\/medsbase.com\/pt-pt\/pt-141\/\">PT-141 (Bremelanotide)<\/a> (melanocortin receptor pharmacology \u2014 sexual-function studies), <a href=\"https:\/\/medsbase.com\/pt-pt\/oxytocin-acetate\/\">Acetato de Oxitocina<\/a> (the hypothalamic posterior-pituitary peptide hormone \u2014 reproductive \/ social bonding), and <a href=\"https:\/\/medsbase.com\/pt-pt\/tesamorelin\/\">Tesamorelin<\/a> (an\u00e1logo do GHRH \u2014 um eixo end\u00f3crino diferente, mas comumente coestudado). Navegue pelo <a href=\"https:\/\/medsbase.com\/pt-pt\/peptides\/\">peptides &amp; compounds catalog<\/a>. <\/p>\n<h2>For\u00e7as e Concentra\u00e7\u00f5es Dispon\u00edveis<\/h2>\n<p>MedsBase stocks HCG (urinary-extracted glycoform) in two lyophilized vial sizes calibrated to typical protocol dose ranges. Each strength is available in 10-vial, 20-vial, or 30-vial pack formats:<\/p>\n<table style=\"width: 100%; border-collapse: collapse; margin: 16px 0;\">\n<thead>\n<tr style=\"background: #2c7cb0; color: #fff;\">\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">For\u00e7a do frasco<\/th>\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">Caso de uso t\u00edpico<\/th>\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">Tamanhos das embalagens<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>5.000 UI<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Standard strength \u2014 single-dose Leydig-cell stimulation, individual-animal HPG-suppression-recovery protocols, ovulation-trigger studies (HCG 5,000 IU is the historical canonical ovulation-induction dose); in-vitro receptor pharmacology at known IU-to-receptor stoichiometry<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">10, 20 ou 30 frascos<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>10.000 UI<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">High-strength vial \u2014 extended-dosing protocols, multi-animal cohort work, high-dose Leydig-cell stimulation studies, multi-week chronic dosing studies; lowest per-IU cost<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">10, 20 ou 30 frascos<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p>Both strengths are the same chemical entity (lyophilized urinary-extracted HCG, \u226599% HPLC purity, WHO 5th International Standard bioassay-confirmed potency). The 10,000 IU vial provides the lowest per-IU cost for large-cohort or chronic-dosing studies; the 5,000 IU vial is convenient for single-dose stimulation experiments or smaller-cohort work where vial-to-vial dosing accuracy matters more than per-IU cost. Users should determine specific dose ranges from peer-reviewed literature appropriate to the protocol. <\/p>\n<h2>Como Compara \u2014 HCG vs Kisspeptina-10<\/h2>\n<p>A HCG e <a href=\"https:\/\/medsbase.com\/pt-pt\/kisspeptin-10\/\">Kisspeptina-10<\/a> s\u00e3o as duas ferramentas pept\u00eddicas do eixo HPG neste cat\u00e1logo, e elas visam camadas completamente diferentes do mesmo eixo. A HCG atua <em>a jusante, no recetor de LH\/CG das c\u00e9lulas de Leydig\/c\u00e9lulas da teca, imitando diretamente o pico de LH \u2014 \u00fatil quando o objetivo \u00e9 estimular a esteroidog\u00e9nese das c\u00e9lulas de Leydig ou desencadear a ovula\u00e7\u00e3o independentemente do estado do eixo HPG a montante. O Kisspeptina-10 atua<\/em>, ao n\u00edvel do recetor LH\/CG das c\u00e9lulas de Leydig\/c\u00e9lulas da teca, mimetizando diretamente o pico de LH \u2014 \u00fatil quando o objetivo \u00e9 estimular a esteroidog\u00e9nese das c\u00e9lulas de Leydig ou desencadear a ovula\u00e7\u00e3o independentemente do estado do eixo HPG. A kisspeptina-10 atua <em>a montante<\/em>, at hypothalamic Kiss1R-expressing GnRH neurons, mimicking the kisspeptin signal that drives endogenous pulsatile GnRH and downstream LH\/FSH release \u2014 useful when the goal is to interrogate the physiological HPG-axis cascade end-to-end. The two compounds are mechanistically complementary, and protocols sometimes combine them to dissect upstream-hypothalamic vs downstream-gonadal contributions to reproductive endocrine output. <\/p>\n<table style=\"width: 100%; border-collapse: collapse; margin: 16px 0;\">\n<thead>\n<tr style=\"background: #2c7cb0; color: #fff;\">\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">Crit\u00e9rio<\/th>\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">HCG<\/th>\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">Kisspeptina-10<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Classe qu\u00edmica<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">P\u00e9ptido linear de 10 res\u00edduos (o fragmento C-terminal bioativo da kisspeptina-54 de cadeia completa)<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">P\u00e9ptido linear de 10 res\u00edduos (o fragmento C-terminal bioativo da kisspeptina-54 completa)<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Peso molecular<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">1.302 Da<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Recetor de LH\/CG (LHCGR, GPCR acoplado a Gs) nas c\u00e9lulas de Leydig\/teca\/granulosa<\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Receptor<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Kiss1R (GPR54, GPCR acoplado a Gq) nos neur\u00f3nios GnRH hipotal\u00e2micos<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Kiss1R (GPR54, recetor acoplado \u00e0 prote\u00edna Gq) nos neur\u00f3nios GnRH hipotal\u00e2micos<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Point of intervention in the HPG axis<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">A jusante \u2014 gonadal (contorna completamente o hipot\u00e1lamo e a hip\u00f3fise)<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">A montante \u2014 hipotal\u00e2mico (impulsiona a cascata fisiol\u00f3gica GnRH \u2192 LH\/FSH \u2192 esteroides gonadais)<\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Best-studied studies focus<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Fun\u00e7\u00e3o das c\u00e9lulas de Leydig, esteroidog\u00e9nese gonadal, recupera\u00e7\u00e3o da supress\u00e3o HPG, desencadeamento da ovula\u00e7\u00e3o, biologia do corpo l\u00fateo, farmacologia do LHCGR<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">GnRH-neuron biology, HPG-axis integration, puberty \/ fertility studies, hypothalamic kisspeptin \/ NKB \/ dynorphin network<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Meia-vida plasm\u00e1tica<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Longo \u2014 33\u201337 h terminal (impulsionado por sialila\u00e7\u00e3o)<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Curto \u2014 minutos (pept\u00eddeo pequeno, sem glicoprote\u00e7\u00e3o)<\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Dose t\u00edpica<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">500\u20135,000 IU SC\/IM em roedores (dose \u00fanica); 250\u2013500 IU\/dia em protocolos cr\u00f3nicos<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">10\u2013100 \u00b5g SC em roedores; administra\u00e7\u00e3o puls\u00e1til em protocolos cr\u00f3nicos<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Estado WADA<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Proibido em todos os momentos em atletas masculinos (S2 \u2014 Hormonas Pept\u00eddicas); isen\u00e7\u00e3o para atletas femininas<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Atualmente n\u00e3o consta na Lista de Subst\u00e2ncias Proibidas da WADA<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p>For studies focused on direct gonadal-cell steroidogenesis, ovulation triggering, or downstream LHCGR pharmacology, HCG is the canonical reference compound. For studies focused on hypothalamic GnRH-neuron biology, HPG-axis integration, or upstream reproductive-endocrine signalling, <a href=\"https:\/\/medsbase.com\/pt-pt\/kisspeptin-10\/\">Kisspeptina-10<\/a> \u00e9 a ferramenta mais direcionada. Consulte tamb\u00e9m <a href=\"https:\/\/medsbase.com\/pt-pt\/pt-141\/\">PT-141 (Bremelanotide)<\/a> for melanocortin-receptor pharmacology and sexual-function studies, and <a href=\"https:\/\/medsbase.com\/pt-pt\/oxytocin-acetate\/\">Acetato de Oxitocina<\/a> for posterior-pituitary peptide-hormone studies. <\/p>\n<div style=\"background: #f4f8fb; border-left: 4px solid #2c7cb0; padding: 14px 18px; margin: 18px 0;\"><strong class=\"mb-bac-water-callout\">\ud83d\udca7 Precisa de \u00e1gua BAC?<\/strong> A reconstitui\u00e7\u00e3o de qualquer frasco liofilizado requer \u00e1gua bacteriost\u00e1tica est\u00e9ril. Combine este produto com o nosso <a href=\"\/pt-pt\/bac-water\/\"><strong>\u00c1gua BAC (\u00c1gua Bacteriost\u00e1tica)<\/strong><\/a> \u2014 frasco multidose de 30 mL, conservado com 0,9% de \u00e1lcool benz\u00edlico, grau USP.<\/div>\n<h2>Armazenamento e Reconstitui\u00e7\u00e3o<\/h2>\n<p><strong>Antes da reconstitui\u00e7\u00e3o:<\/strong> armazenar frascos liofilizados refrigerados a 2\u20138 \u00b0C na embalagem original para stock de trabalho a curto prazo. Para armazenamento a longo prazo, congelar frascos n\u00e3o abertos a \u221220 \u00b0C (est\u00e1vel \u226536 meses a \u221220 \u00b0C; \u226518 meses a 2\u20138 \u00b0C). O HCG liofilizado \u00e9 razoavelmente est\u00e1vel porque as subunidades \u03b1 e \u03b2 s\u00e3o mantidas juntas por intera\u00e7\u00f5es hidrof\u00f3bicas e liga\u00e7\u00f5es de hidrog\u00e9nio que n\u00e3o s\u00e3o perturbadas no estado liofilizado, mas a prote\u00edna \u00e9 sens\u00edvel \u00e0 exposi\u00e7\u00e3o \u00e0 humidade e ao ciclo t\u00e9rmico. <strong>Procedimento de reconstitui\u00e7\u00e3o:<\/strong> para o frasco de 5.000 UI, injete 1,0 mL de \u00e1gua bacteriost\u00e1tica pela parede lateral do frasco (n\u00e3o diretamente sobre o composto liofilizado) \u2014 isto produz uma solu\u00e7\u00e3o de trabalho de 5.000 UI\/mL. Para o frasco de 10.000 UI, injete 2,0 mL de \u00e1gua bacteriost\u00e1tica para obter a mesma solu\u00e7\u00e3o de trabalho de 5.000 UI\/mL, ou 1,0 mL para uma solu\u00e7\u00e3o de alta concentra\u00e7\u00e3o de 10.000 UI\/mL. <strong>Agitar suavemente para dissolver \u2014 n\u00e3o agitar vigorosamente, n\u00e3o usar vortex.<\/strong> A mistura de alto cisalhamento dissocia o heterod\u00edmero \u03b1\/\u03b2 e destr\u00f3i a bioatividade de liga\u00e7\u00e3o ao LHCGR. O composto liofilizado \u00e0 base de manitol geralmente dissolve-se em 30\u201360 segundos com agita\u00e7\u00e3o suave. <strong>Regras cr\u00edticas de armazenamento para material reconstitu\u00eddo:<\/strong> uma vez reconstitu\u00eddo, armazenar a 2\u20138 \u00b0C e utilizar dentro de 30 dias. <strong>N\u00e3o congele a HCG reconstitu\u00edda<\/strong> \u2014 freeze-thaw cycles dissociate the heterodimer and irreversibly destroy bioactivity. Protect from light. Discard if cloudiness, particulates, or marked colour change appears. For protocols that require multiple aliquots, prepare the aliquots at the time of reconstitution and store them at 2\u20138 \u00b0C separately rather than freezing \u2014 short-term refrigerated storage retains bioactivity better than even single freeze-thaw cycles. <\/p>\n<h2>Perguntas Frequentes<\/h2>\n<h3>Qual \u00e9 a diferen\u00e7a entre HCG extra\u00edda da urina (uHCG) e HCG recombinante (rHCG \/ coriogonadotropina alfa)?<\/h3>\n<p><strong>HCG extra\u00edda da urina<\/strong> (o que fornecemos, CAS 9002-61-3) \u00e9 purificada a partir da urina coletada de mulheres gr\u00e1vidas usando cromatografia de troca i\u00f3nica e de filtra\u00e7\u00e3o em gel. <strong>HCG recombinante<\/strong> (coriogonadotropina alfa, CAS 56832-30-5; prepara\u00e7\u00f5es cl\u00ednicas Ovidrel \/ Ovitrelle) \u00e9 produzida em c\u00e9lulas CHO a partir de cDNAs clonados das subunidades \u03b1 e \u03b2 da HCG. As duas formas t\u00eam a mesma sequ\u00eancia de amino\u00e1cidos e ligam-se ao LHCGR com a mesma afinidade, mas os padr\u00f5es de glicosila\u00e7\u00e3o diferem ligeiramente entre o material derivado da urina e o expresso em c\u00e9lulas CHO. Compara\u00e7\u00f5es publicadas de bioensaios diretos relatam pot\u00eancia in-vivo amplamente equivalente, com a rHCG a mostrar padr\u00f5es de glicosila\u00e7\u00e3o ligeiramente mais consistentes entre lotes e a uHCG a mostrar um conte\u00fado de \u00e1cido si\u00e1lico ligeiramente superior, t\u00edpico da glicosila\u00e7\u00e3o placent\u00e1ria. <\/p>\n<h3>Quantas UI correspondem a 1 mg de HCG?<\/h3>\n<p>O material de refer\u00eancia do 5\u00ba Padr\u00e3o Internacional da OMS define a pot\u00eancia da HCG em aproximadamente 9.300 UI por mg de p\u00e9ptido puro. Na pr\u00e1tica: um frasco de 5.000 UI cont\u00e9m ~0,54 mg de p\u00e9ptido; um frasco de 10.000 UI cont\u00e9m ~1,08 mg. A UI \u00e9 uma unidade definida por bioensaio que reflete a pot\u00eancia de liga\u00e7\u00e3o ao LHCGR em vez da massa, e a rela\u00e7\u00e3o UI\/mg varia ligeiramente entre glicoformas e entre lotes \u2014 raz\u00e3o pela qual a HCG de grau farmac\u00eautico \u00e9 rotulada em UI em vez de mg. <\/p>\n<h3>What published dose ranges have been used in rodent studies?<\/h3>\n<p>Single-bolus rodent protocols typically use 50\u2013250 IU SC or IM for cAMP \/ receptor-internalization studies, and 500\u20135,000 IU SC for sustained testosterone-output protocols (3\u20137 day duration of action per bolus). Chronic protocols use 100\u2013500 IU\/day for 2\u20134 weeks. The published ovulation-trigger dose in rodents is typically 5\u201310 IU per mouse or 10\u201350 IU per rat IP. In-vitro Leydig-cell stimulation protocols typically use 0.1\u201310 IU\/mL in culture medium. Users should consult primary literature appropriate to the species, model, and endpoint of interest. <\/p>\n<h3>Porque \u00e9 que a HCG tem uma meia-vida muito mais longa do que a LH?<\/h3>\n<p>A subunidade \u03b2 da HCG transporta quatro glicanos ligados a N e quatro glicanos ligados a O, com um conte\u00fado excecionalmente elevado de \u00e1cido si\u00e1lico (NeuAc) nas posi\u00e7\u00f5es terminais destes glicanos. O recetor da asialoglicoprote\u00edna (ASGR) nos hepat\u00f3citos \u00e9 a principal via pela qual as hormonas da fam\u00edlia das gonadotropinas s\u00e3o eliminadas da circula\u00e7\u00e3o \u2014 o ASGR reconhece res\u00edduos terminais de galactose \/ N-acetilgalactosamina expostos ap\u00f3s a remo\u00e7\u00e3o do \u00e1cido si\u00e1lico terminal pela sialidase. Como a subunidade \u03b2 da HCG est\u00e1 t\u00e3o intensamente e terminalmente sialilada, a depura\u00e7\u00e3o mediada pelo ASGR hep\u00e1tico \u00e9 muito mais lenta do que para a subunidade \u03b2 da LH, que est\u00e1 menos sialilada, resultando numa diferen\u00e7a dram\u00e1tica na meia-vida (HCG 33\u201337 h vs LH ~20 min). <\/p>\n<h3>Porque \u00e9 que a HCG reconstitu\u00edda n\u00e3o pode ser congelada?<\/h3>\n<p>A HCG \u00e9 um heterod\u00edmero de duas subunidades n\u00e3o covalentemente associadas. A intera\u00e7\u00e3o \u03b1\/\u03b2 \u00e9 est\u00e1vel no liofilizado (porque n\u00e3o h\u00e1 \u00e1gua para as subunidades se separarem) e est\u00e1vel em solu\u00e7\u00e3o aquosa refrigerada a 2\u20138 \u00b0C (porque a cin\u00e9tica de dissocia\u00e7\u00e3o \u00e9 lenta a baixas temperaturas). Mas a forma\u00e7\u00e3o de cristais de gelo durante o congelamento separa fisicamente as subunidades, e uma vez dissociadas, elas reassociam-se de forma ineficiente ap\u00f3s o descongelamento. O resultado \u00e9 que a HCG congelada e descongelada ret\u00e9m uma grande fra\u00e7\u00e3o de imunorreatividade (a subunidade \u03b2 ainda \u00e9 detet\u00e1vel por anticorpos), mas perde uma grande fra\u00e7\u00e3o de bioatividade (as subunidades dissociadas n\u00e3o interagem eficientemente com o LHCGR). A HCG liofilizada pode ser congelada e \u00e9 est\u00e1vel a \u221220 \u00b0C; a HCG reconstitu\u00edda n\u00e3o pode. <\/p>\n<h3>Qual \u00e9 o estatuto regulamentar da HCG na WADA?<\/h3>\n<p>A HCG est\u00e1 na Lista de Subst\u00e2ncias Proibidas da Ag\u00eancia Mundial Antidopagem (WADA) na classe S2 (Hormonas Pept\u00eddicas, Fatores de Crescimento, Subst\u00e2ncias Relacionadas e Mim\u00e9ticos). \u00c9 proibida em todas as circunst\u00e2ncias \u2014 tanto em competi\u00e7\u00e3o como fora de competi\u00e7\u00e3o \u2014 para <strong>apenas atletas masculinos<\/strong>. Female athletes are exempt because HCG is a natural pregnancy hormone and therefore detectable in any pregnant woman regardless of administration. Users conducting human-subject studies with HCG need to be aware of this regulatory status. For clinical in-vitro and rodent in-vivo studies the WADA status is informational only. <\/p>\n<h3>Can HCG be combined with Kisspeptin-10, FSH, or testosterone in protocols?<\/h3>\n<p>Yes \u2014 these compounds target different layers of the HPG axis (upstream, mid, downstream) and are commonly combined in studies that aims to dissect axis integration. The most-published combinations are HCG with FSH (or FSH analogues) for spermatogenesis or follicular-development studies; HCG with <a href=\"https:\/\/medsbase.com\/pt-pt\/kisspeptin-10\/\">Kisspeptina-10<\/a> for upstream-vs-downstream dissection; HCG with exogenous testosterone (for HPG-suppression-recovery, where the testosterone suppresses LH and HCG bypasses the suppression). Reconstitute each separately and follow each compound&#8217;s specific storage rules \u2014 HCG in particular must not be frozen reconstituted (see above). <\/p>\n<h3>How does this pharmaceutical-grade HCG compare with the branded clinical preparations (Eutrig, HUCOG, ZyHCG, Pregnyl, Ovidrel)?<\/h3>\n<p>The branded clinical preparations are urinary-extracted HCG (Eutrig HP, HUCOG, ZyHCG, Pregnyl) or recombinant HCG (Ovidrel \/ Ovitrelle) packaged under various manufacturer SKUs for clinical use in fertility and reproductive medicine. The pharmaceutical-grade HCG supplied here is the same urinary-extracted glycoform (uHCG, CAS 9002-61-3) at \u226599% HPLC purity, supplied without a clinical-use label and intended for clinical studies only. Users seeking clinical-use HCG should obtain it through a clinical supply chain; users seeking pharmaceutical-grade material for in-vitro receptor pharmacology, rodent in-vivo work, or other clinical applications can use the material supplied here. <!-- medsbase-related-alts-v1 --><\/p>\n<h2>Other Peptides for HPG-Axis and Reproductive Studies<\/h2>\n<ul>\n<li><a href=\"\/pt-pt\/kisspeptin-10\/\"><strong>Kisspeptina-10<\/strong><\/a> \u2014 Agonista hipotal\u00e2mico Kiss1R \u2014 regulador do eixo HPG a montante, impulsiona a pulsatileidade do GnRH<\/li>\n<li><a href=\"\/pt-pt\/pt-141\/\"><strong>PT-141 (Bremelanotide)<\/strong><\/a> \u2014 Melanocortin-4 receptor agonist \u2014 sexual-function studies<\/li>\n<li><a href=\"\/pt-pt\/oxytocin-acetate\/\"><strong>Acetato de Oxitocina<\/strong><\/a> \u2014 Posterior pituitary nonapeptide \u2014 reproductive and social bonding<\/li>\n<li><a href=\"\/pt-pt\/tesamorelin\/\"><strong>Tesamorelin<\/strong><\/a> \u2014 An\u00e1logo do GHRH \u2014 eixo end\u00f3crino diferente, frequentemente coestudado<\/li>\n<li><a href=\"\/pt-pt\/sermorelin\/\"><strong>Sermorelin<\/strong><\/a> \u2014 GHRH 1-29 analogue \u2014 pituitary GH-axis studies<\/li>\n<li><a href=\"\/pt-pt\/bac-water\/\"><strong>\u00c1gua BAC (\u00c1gua Bacteriost\u00e1tica)<\/strong><\/a> \u2014 Necess\u00e1rio para reconstituir qualquer frasco liofilizado \u2014 diluente est\u00e9ril, conservado com 0,9% de \u00e1lcool benz\u00edlico<\/li>\n<\/ul>","protected":false},"excerpt":{"rendered":"<p>\u2705 Hormona glicoproteica heterodim\u00e9rica \u2014 subunidade \u03b1 + \u03b2 (~244 aa, ~36.7 kDa)<br \/>\n\u2705 Agonista can\u00f3nico do recetor LH\/CG (LHCGR) \u2014 impulsiona a esteroidog\u00e9nese das c\u00e9lulas de Leydig<br \/>\n\u2705 Meia-vida plasm\u00e1tica longa (33\u201337 h) vs LH (~20 min) \u2014 impulsionada por \u00e1cido si\u00e1lico<br \/>\n\u2705 Glicoforma extra\u00edda da urina (uHCG, CAS 9002-61-3), \u226599% HPLC, bioensaio IS 5\u00aa OMS<br \/>\n\u2705 For clinical studies only \u2014 distinct from branded clinical preparations<\/p>\n<p><strong>HCG (Pharmaceutical Grade)<\/strong> cont\u00e9m Gonadotrofina Cori\u00f3nica Humana extra\u00edda da urina.<\/p>","protected":false},"featured_media":71445,"comment_status":"open","ping_status":"closed","template":"","meta":[],"product_brand":[],"product_cat":[5426],"product_tag":[6490,3826,6492,5663,6491,6493,6494],"class_list":["post-71436","product","type-product","status-publish","has-post-thumbnail","product_cat-peptides","product_tag-gonadotropin","product_tag-hcg","product_tag-hpg-axis","product_tag-human-chorionic-gonadotropin","product_tag-lhcgr-agonist","product_tag-reproductive-research","product_tag-research-peptide","first","instock","shipping-taxable","purchasable","product-type-variable","has-default-attributes"],"acf":[],"_links":{"self":[{"href":"https:\/\/medsbase.com\/pt-pt\/wp-json\/wp\/v2\/product\/71436","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/medsbase.com\/pt-pt\/wp-json\/wp\/v2\/product"}],"about":[{"href":"https:\/\/medsbase.com\/pt-pt\/wp-json\/wp\/v2\/types\/product"}],"replies":[{"embeddable":true,"href":"https:\/\/medsbase.com\/pt-pt\/wp-json\/wp\/v2\/comments?post=71436"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/medsbase.com\/pt-pt\/wp-json\/wp\/v2\/media\/71445"}],"wp:attachment":[{"href":"https:\/\/medsbase.com\/pt-pt\/wp-json\/wp\/v2\/media?parent=71436"}],"wp:term":[{"taxonomy":"product_brand","embeddable":true,"href":"https:\/\/medsbase.com\/pt-pt\/wp-json\/wp\/v2\/product_brand?post=71436"},{"taxonomy":"product_cat","embeddable":true,"href":"https:\/\/medsbase.com\/pt-pt\/wp-json\/wp\/v2\/product_cat?post=71436"},{"taxonomy":"product_tag","embeddable":true,"href":"https:\/\/medsbase.com\/pt-pt\/wp-json\/wp\/v2\/product_tag?post=71436"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}